This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Meridian Bioscience Receives FDA Clearance For New Premier ™ C. Difficile GDH Assay

Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for a new Clostridium difficile immunoassay named Premier™ C. difficile GDH. This product expands the Company’s existing portfolio of C. difficile tests and has been available in Europe and the rest of world since October of 2010. The assay detects a common antigen produced by toxigenic and non-toxigenic forms of C. difficile bacteria. Toxigenic forms of C. difficile are frequently associated with hospital and community acquired diarrhea resulting from antibiotic therapy and, in severe cases, can cause a life-threatening inflammation of the colon. Premier™ GDH is used by laboratories that want to screen patients with diarrhea for both forms of C. difficile. To differentiate those patients at risk of disease with toxin-producing forms of C. difficile, GDH-positive samples should be re-tested with toxin-detecting tests such as Meridian’s Premier™ Toxins A&B or Immuno Card ® Toxins A&B, or with a molecular amplification assay, such as Meridian’s illumigene ® C. difficile test.

Jack Kraeutler, Chief Executive Officer, commented, “ C. difficile can be a very dangerous infection that may lead to severe consequences for both patients and the healthcare institutions that care for them. Clearance of our new Premier™ C. difficile GDH test continues the Company’s long history of breakthrough products for the detection and identification of C. difficile. Meridian introduced its first latex based assay in March, 1990. Shortly thereafter, Meridian scientists confirmed that the “latex-reactive protein” of C. difficile was in fact a glutamate dehydrogenase and not a toxin, as previously thought. Continuing innovation allowed Meridian to launch the first commercially available GDH enzyme immunoassay (Immuno Card ® C. difficile GDH) in January 1993 that was significantly more sensitive than the previous latex based tests. This third generation GDH assay, built on 20 years of C. difficile expertise, should set a new standard for GDH identification and, along with our toxin detection assays and our new illumigene ® molecular platform, affirms our unique position as the one IVD Company that offers complete solutions for C. difficile detection.”

FORWARD LOOKING STATEMENTS

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs